Journal: Cancer Immunology, Immunotherapy
Article Title: ADRB3 expression in tumor cells is a poor prognostic factor and promotes proliferation in non-small cell lung carcinoma
doi: 10.1007/s00262-020-02627-3
Figure Lengend Snippet: Mice lacking ADRB3 are protected from tumor and inflammation. a LLC cancer cells were s.c. inoculated into ADRB3 +/+ and ADRB3 −/− mice ( n = 8) on day 0. primary tumors were measured with a calipers. Points , average diameters of primary tumor as a function of days after tumor inoculation; All data are expressed as group means ± SEM. * P < 0.05, # P < 0.01 compared with ADRB3 +/+ mice. b Serum IL-2, IL-5 and IL-6 as measured by Multiplex ELISA Array were significantly decreased in ADRB3 −/− mice ( n = 8) compared with the ADRB3 +/+ group. c Count of white blood cell and monocytes of the ADRB3 −/− mice and ADRB3 +/+ mice. d Percentage of monocyte and lymphocytes of the ADRB3 −/− mice and ADRB3 +/+ mice. e NLR of the ADRB3 −/− mice and ADRB3 +/+ mice. EDTA anti-coagulated blood samples were used to obtain a complete blood count with automated hematology analyzer. f Representative immunostaining of ADRB3, CD68, MPO, IL-6, and IFN- β in lung tissues of ADRB3 −/− and ADRB3 +/+ mice. Scale bars, 50 μm
Article Snippet: MPO was determined using the Mouse MPO Quantikine ELISA Kits (R&D Systems,) according to manufacturer's instructions.
Techniques: Multiplex Assay, Enzyme-linked Immunosorbent Assay, Immunostaining